Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Nemus Biosciences

  • Brian Murphy, Nemus Bioscience

NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. These molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS Bioscience Inc. is developing novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

  • Date:Tuesday, February 12
  • Time:10:15 AM - 10:30 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23561
  • Goal for Presentation:Build Awareness and Potential of Cannabinoid-based Science
  • Company Website:www.nemusbioscience.com
  • Company HQ City:Long Beach
  • Company HQ State:California
  • Company HQ Country:United States
  • Market Cap:$43 Million USD
  • Ticker:NMUS
  • Exchange:OTC
  • CEO/Top Company Official:Dr. Brian Murphy
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:NB 1111
  • Development Phase of Primary Product:Pre-Clinical
Speakers
Brian Murphy
Nemus Bioscience
Back